ScripMetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy
Pink SheetOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
ScripOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
ScripThe fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r